Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy

[1]  R. Fossmark,et al.  Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[2]  H. Kuwano,et al.  A case of mixed adenoneuroendocrine carcinoma of the stomach with focal intestinal metaplasia and hypergastrinemia. , 2015, International surgery.

[3]  Jian S. Zhou,et al.  Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation. , 2015, World journal of gastroenterology.

[4]  Sunil Dacha,et al.  Hypergastrinemia , 2015, Gastroenterology report.

[5]  H. Sugihara,et al.  Progression risk assessments of individual non-invasive gastric neoplasms by genomic copy-number profile and mucin phenotype , 2015, BMC Medical Genomics.

[6]  R. Fossmark,et al.  Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach , 2015, Digestive Diseases and Sciences.

[7]  Huan Song,et al.  Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. , 2014, The Cochrane database of systematic reviews.

[8]  J. Kang.  Chromosome 8q as the most frequent target for amplification in early gastric carcinoma , 2014, Oncology letters.

[9]  H. Sugihara,et al.  Precursor‐derived versus de‐novo carcinogenesis depends on lineage‐specific mucin phenotypes of intramucosal gland‐forming gastric neoplasms , 2013, Histopathology.

[10]  Massimo Rugge,et al.  Management of gastric polyps: an endoscopy-based approach. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  S. Nasseri-Moghaddam,et al.  Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? , 2013, Archives of Iranian medicine.

[12]  R. Mårvik,et al.  Gastric carcinoids after long‐term use of a proton pump inhibitor , 2012, Alimentary pharmacology & therapeutics.

[13]  T. Viset,et al.  Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor , 2012, Scandinavian journal of gastroenterology.

[14]  G. Qvigstad,et al.  Animal Models to Study the Role of Long-Term Hypergastrinemia in Gastric Carcinogenesis , 2010, Journal of biomedicine & biotechnology.

[15]  Teodoro Oscanoa Espinoza.  [Safety of the proton pump inhibitors]. , 2011, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[16]  H. Sugihara,et al.  Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori , 2010, Gut.

[17]  D. Ito,et al.  Gastric Carcinoid with Hypergastrinemia: Report of Three Cases , 2010, Case reports in medicine.

[18]  M. Walker,et al.  The management of gastric polyps , 2010, Gut.

[19]  N. Kassam,et al.  Safety of the long-term use of proton pump inhibitors. , 2010, World journal of gastroenterology.

[20]  M. Hongo,et al.  Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan , 2010, Journal of Gastroenterology.

[21]  H. Grabsch,et al.  High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers , 2009, Virchows Archiv.

[22]  G. Qvigstad,et al.  Gastric cancer: animal studies on the risk of hypoacidity and hypergastrinemia. , 2008, World journal of gastroenterology.

[23]  M. Vieth,et al.  Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach , 2006, Gastric Cancer.

[24]  A. Ashworth,et al.  Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. , 2006, Genomics.

[25]  M. Stolte,et al.  Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? , 2005, Virchows Archiv.

[26]  T. Hattori,et al.  Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach , 2005, Journal of Cancer Research and Clinical Oncology.

[27]  Robert Kincaid,et al.  Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Fujishima,et al.  Possible neoplastic transformation within gastric hyperplastic polyp , 1995, Surgical Endoscopy.

[29]  T. Ohkusa,et al.  Endoscopic, Histological and Serologic Findings of Gastric Hyperplastic Polyps after Eradication of Helicobacter pylori: Comparison between Responder and Non-Responder Cases , 2004, Digestion.

[30]  K. Baisley,et al.  Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects , 2002, Alimentary pharmacology & therapeutics.

[31]  J. Kupryjańczyk,et al.  Malignant transformation of gastric hyperplastic polyps. , 2002, American journal of clinical pathology.

[32]  H. Sugihara,et al.  MUC gene expression and histogenesis of adenocarcinoma of the stomach , 2001, International journal of cancer.

[33]  M. Stolte.  Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. , 2001, The American journal of surgical pathology.

[34]  Vikesh K. Singh,et al.  Hyperplastic Polyps of the Stomach: Associations With Histologic Patterns of Gastritis and Gastric Atrophy , 2001, The American journal of surgical pathology.

[35]  H. Mitomi,et al.  p53, but not c-Ki-ras, mutation and down-regulation of p21WAF1/CIP1 and cyclin D1 are associated with malignant transformation in gastric hyperplastic polyps. , 2001, American journal of clinical pathology.

[36]  R. Seruca,et al.  Microsatellite instability in hyperplastic and adenomatous polyps of the stomach , 1999, Cancer.

[37]  C. Bordi,et al.  Pathogenesis of ECL cell tumors in humans. , 1998, The Yale journal of biology and medicine.

[38]  G. Ginsberg,et al.  Gastric polyps: relationship of size and histology to cancer risk. , 1996, The American journal of gastroenterology.

[39]  T. Nakayama,et al.  Carcinoma in gastric hyperplastic polyps. A phenotypic study. , 1996, Digestive diseases and sciences.

[40]  J. Pachlewski,et al.  Malignant transformation of benign epithelial gastric polyps. , 1995, The American journal of gastroenterology.

[41]  M. Stolte,et al.  Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. , 1995, Zeitschrift fur Gastroenterologie.

[42]  S. Wahl,et al.  p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. , 1993, The American journal of gastroenterology.

[43]  M. Franceschi,et al.  Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study. , 1993, Clinical nephrology.

[44]  N. Arber,et al.  Gastric polypoid lesions--an eight-year study. , 1993, Hepato-gastroenterology.

[45]  S. Ascani,et al.  Association between histologic type of polyp and carcinoma in the stomach. , 1992, Gastrointestinal endoscopy.

[46]  M. Stolte,et al.  Omeprazole-induced pseudohypertrophy of gastric parietal cells. , 1992, Zeitschrift fur Gastroenterologie.

[47]  W. Creutzfeldt,et al.  Histopathological classification of nonantral gastric endocrine growths in man. , 1988, Digestion.

[48]  E. Harju.  Gastric polyposis and malignancy , 1986, The British journal of surgery.

[49]  T. Hattori.  Morphological range of hyperplastic polyps and carcinomas arising in hyperplastic polyps of the stomach. , 1985, Journal of clinical pathology.

[50]  J. Mcguigan,et al.  Serum and tissue gastrin concentrations in patients with carcinoma of the stomach. , 1973, Gastroenterology.